| Ms Laura Elisabeth Farina, MA CCC-SLP | |
|
7218 Park Heights Ave, Pikesville, MD 21208-5474 | |
| (410) 318-8000 | |
| Not Available |
| Full Name | Ms Laura Elisabeth Farina |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 7218 Park Heights Ave, Pikesville, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093965527 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1111 (Missouri) | Secondary |
| 235Z00000X | Speech-language Pathologist | 2692 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Laura Elisabeth Farina, MA CCC-SLP 2035 Kays Mill Rd, Finksburg, MD 21048-2011 Ph: (443) 929-7287 | Ms Laura Elisabeth Farina, MA CCC-SLP 7218 Park Heights Ave, Pikesville, MD 21208-5474 Ph: (410) 318-8000 |
News Archive
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.
The University of Texas MD Anderson Cancer Center and Varian today announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.
Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
› Verified 1 days ago
Efrona Shane, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Sudbrook Ln Ste A, Pikesville, MD 21208 Phone: 410-358-1997 | |
Chloe Yates, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Sudbrook Ln Ste A, Pikesville, MD 21208 Phone: 410-358-1997 | |
Sarai A Brown, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Sudbrook Ln Ste A, Pikesville, MD 21208 Phone: 410-358-1997 | |
Ms. Alexa Kathleen Mikk, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Sudbrook Ln Ste A, Pikesville, MD 21208 Phone: 410-358-1997 | |
Caroline Rose Gerlach, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Sudbrook Ln, Pikesville, MD 21208 Phone: 410-358-1997 | |
Alexandra Lindyn Niemiec, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Sudbrook Ln Ste A, Pikesville, MD 21208 Phone: 410-358-1997 |